Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data

Schizophrenia Research

Volumn 153, Issue 1-3, 2014, Pages 184-188

  Yoshida, Kazunari ^a   Bies, Robert R ^b,c,d   Suzuki, Takefumi ^a,e   Remington, Gary ^b,f   Pollock, Bruce G ^b,f   Mizuno, Yuya ^a   Mimura, Masaru ^a   Uchida, Hiroyuki ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Indiana Clinical and Translational Sciences Institute   (United States)

^e Inokashira Hospital   (Japan)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abnormal involuntary movement; Antipsychotics; CATIE; Dopamine D2 receptor; Schizophrenia; Tardive dyskinesia

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT; PROTEIN BINDING;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; CLINICAL ANTIPSYCHOTIC TRIAL IN INTERVENTION EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TARDIVE DYSKINESIA; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; MOVEMENT DISORDERS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84895785682     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.01.017     Document Type: Article

References (44)

1. Beal B., Sheiner L. NONMEM User's Guide, Part I 1992, University of California, San Francisco.
2. Bigos K.L., Bies R.R., Pollock B.G. Population pharmacokinetics in geriatric psychiatry. Am. J. Geriatr. Psychiatry 2006, 14(12):993-1003.
3. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Kirshner M.A., Schneider L.S., Bies R.R. Sex, race, and smoking impact olanzapine exposure. J. Clin. Pharmacol. 2008, 48(2):157-165.
4. Blanchet P.J. Antipsychotic drug-induced movement disorders. Can. J. Neurol. Sci. 2003, 30(Suppl. 1):S101-S107.
5. Carey R.J., DeVeaugh-Geiss J. Treatment schedule as a determinant of the development of tolerance to haloperidol. Psychopharmacology (Berl.) 1984, 82(3):164-167.
6. Chakos M.H., Alvir J.M., Woerner M.G., Koreen A., Geisler S., Mayerhoff D., Sobel S., Kane J.M., Borenstein M., Lieberman J.A. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry 1996, 53(4):313-319.
7. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 2004, 161(3):414-425.
8. Dossenbach M., Erol A., el Mahfoud Kessaci M., Shaheen M.O., Sunbol M.M., Boland J., Hodge A., O'Halloran R.A., Bitter I. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J. Clin. Psychiatry 2004, 65(3):312-321.
9. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr. Bull. 1997, 23(4):583-609.
10. Feng Y., Pollock B.G., Coley K., Marder S., Miller D., Kirshner M., Aravagiri M., Schneider L., Bies R.R. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br. J. Clin. Pharmacol. 2008, 66(5):629-639.
11. Fitzgerald P.B., Kapur S., Remington G., Roy P., Zipursky R.B. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl.) 2000, 149(1):1-5.
12. Haro J.M., Edgell E.T., Frewer P., Alonso J., Jones P.B. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr. Scand. Suppl. 2003, 416:7-15.
13. Haro J.M., Edgell E.T., Jones P.B., Alonso J., Gavart S., Gregor K.J., Wright P., Knapp M. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr. Scand. 2003, 107(3):222-232.
14. Ikai S., Remington G., Suzuki T., Takeuchi H., Tsuboi T., Den R., Hirano J., Tsunoda K., Nishimoto M., Watanabe K., Mimura M., Mamo D., Uchida H. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J. Clin. Psychiatry 2012, 73(8):1147-1152.
15. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(7):1081-1090.
16. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001, 50(11):873-883.
17. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 1995, 57(10):L103-L107.
18. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
19. Kontny N.E., Wurthwein G., Joachim B., Boddy A.V., Krischke M., Fuhr U., Thompson P.A., Jorger M., Schellens J.H., Hempel G. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3years. Cancer Chemother. Pharmacol. 2013, 71(3):749-763.
20. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can. J. Psychiatry 2005, 50(9):541-547.
21. Marsot A., Boulamery A., Bruguerolle B., Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin. Pharmacokinet. 2012, 51(1):1-13.
22. Miller D.D., McEvoy J.P., Davis S.M., Caroff S.N., Saltz B.L., Chakos M.H., Swartz M.S., Keefe R.S., Rosenheck R.A., Stroup T.S., Lieberman J.A. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr. Res. 2005, 80(1):33-43.
23. Mizuno Y., Bies R.R., Remington G., Mamo D.C., Suzuki T., Pollock B.G., Tsuboi T., Watanabe K., Mimura M., Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 37(1):182-187.
24. Moriguchi S., Bies R.R., Remington G., Suzuki T., Mamo D.C., Watanabe K., Mimura M., Pollock B.G., Uchida H. Estimated dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J. Clin. Psychopharmacol. 2013, 33(5):682-685.
25. Oosthuizen P.P., Emsley R.A., Maritz J.S., Turner J.A., Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J. Clin. Psychiatry 2003, 64(9):1075-1080.
26. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Curr. Opin. Psychiatry 2007, 20(2):131-137.
27. Remington G., Seeman P., Feingold A., Mann S., Shammi C., Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011, 72(8):1042-1048.
28. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27(11):2979-2986.
29. Samaha A.N., Reckless G.E., Seeman P., Diwan M., Nobrega J.N., Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 2008, 64(2):145-152.
30. Sheiner L.B., Rosenberg B., Marathe V.V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J. Pharmacokinet. Biopharm. 1977, 5(5):445-479.
31. Soares-Weiser K., Fernandez H.H. Tardive dyskinesia. Semin. Neurol. 2007, 27(2):159-169.
32. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29(1):15-31.
33. Tenback D.E., van Harten P.N. Epidemiology and risk factors for (tardive) dyskinesia. Int. Rev. Neurobiol. 2011, 98:211-230.
34. Tenback D.E., van Harten P.N., Slooff C.J., Belger M.A., van Os J. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J. Clin. Psychiatry 2005, 66(9):1130-1133.
35. Tenback D.E., van Harten P.N., van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov. Disord. 2009, 24(16):2309-2315.
36. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry 1997, 154(9):1248-1254.
37. Turrone P., Remington G., Kapur S., Nobrega J.N. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl.) 2003, 165(2):166-171.
38. Turrone P., Remington G., Kapur S., Nobrega J.N. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol. Psychiatry 2005, 57(4):406-411.
39. Uchida H., Pollock B.G., Bies R.R., Mamo D.C. Predicting age-specific dosing of antipsychotics. Clin. Pharmacol. Ther. 2009, 86(4):360-362.
40. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Predicting dopamine D(2) receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31(3):318-325.
41. Uchida H., Mamo D.C., Pollock B.G., Suzuki T., Tsunoda K., Watanabe K., Mimura M., Bies R.R. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther. Drug Monit. 2012, 34(2):182-187.
42. Wessels A.M., Bies R.R., Pollock B.G., Schneider L.S., Lieberman J.A., Stroup S., Li C.H., Coley K., Kirshner M.M., Marder S.R. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J. Clin. Pharmacol. 2011, 51(11):1587-1591.
43. WHO.Collaborating centre for drug statistics methodology Available at:, (Accessed December 11, 2013). http://www.whocc.no/atcddd/.
44. Woods S.W., Morgenstern H., Saksa J.R., Walsh B.C., Sullivan M.C., Money R., Hawkins K.A., Gueorguieva R.V., Glazer W.M. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J. Clin. Psychiatry 2010, 71(4):463-474.